MediciNova logo
MediciNova
MNOV | NASDAQ
Chart Builder DCF Calculator
$1.34
-$0.05 (-3.94%)
At close: Nov 16, 2026, 4:00 PM ET
$1.33
-$0.01 (-0.60%)
After-hours: Nov 16, 2026, 7:30 PM ET

MediciNova Company Profile

Company profile explained

Company Profile

MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.

Key Executives

Name Position
Yuichi Iwaki Co-Founder, President, Chief Executive Officer & Chairman
Jason J. Kruger Chief Financial Officer & Principal Financial Officer
David H. Crean Chief Business Officer
Kazuko Matsuda Senior VP, Chief Medical Officer & Director

Latest SEC Filings

Date Type Title
Oct 30, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Sep 29, 2026 4 Filing
Sep 29, 2026 SC 13D/A [Amend] Filing
Sep 28, 2026 8-K Current Report
Sep 02, 2026 8-K Current Report
Aug 19, 2026 8-K Current Report
Aug 13, 2026 10-Q Quarterly Report
Jun 25, 2026 4 Filing
Jun 25, 2026 4 Filing
Jun 25, 2026 4 Filing
View All SEC Filings ➞
MediciNova
MediciNova logo
Country United States
IPO Date Dec 8, 2006
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Yuichi Iwaki

Contact Details

4275 Executive Square La Jolla, California 92037 United States

Stock Details

Ticker Symbol MNOV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001226616
CUSIP Number 58468P206
ISIN Number US58468P2065
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.